Currently, the established prognostic factors (histologic grade, stage and prostate-specific antigen (PSA) level at diagnosis (Albertsen et al, 1998; Barry et al, 2001) are insufficient to separate prostate cancer patients who are at high risk for cancer progression from those who are likely to die of another cause. This evidence concerns the gene KLK3 and prostate carcinoma.